HC Wainwright & Co. Maintains Buy on Eupraxia Pharmaceuticals, Lowers Price Target to $11

Benzinga Newsdesk www.benzinga.com Negative 63.1%

Neg 63.1% Neu 0% Pos 0%

HC Wainwright & Co. analyst Brandon Folkes maintains Eupraxia Pharmaceuticals (NASDAQ:EPRX) with a Buy and lowers the price target from $12 to $11.